Latest Pharmaceuticals News

Page 2 of 40
Acrux has received clearer FDA guidance for Phase III trials of its female testosterone spray, including potential three-year data exclusivity if the product reaches submission. The company also reported positive September-quarter operating cash flow, but that result was largely driven by a $1.977 million R&D tax rebate and Acrux says it is still pursuing funding for the clinical programme.
Victor Sage
Victor Sage
19 Oct 2026
Algorae has secured exclusive Australian commercial rights across eight Umedica-branded molecules while separately advancing a Umedica-supplied product towards regulatory approval. The broader arrangement remains partly non-binding, with financial terms undisclosed and TGA approval still pending.
Victor Sage
Victor Sage
19 Oct 2026
Mayne Pharma has settled its final US Paragraph IV patent dispute over IMVEXXY with Teva, setting a potential generic entry date of 2 September 2032. The agreement removes ongoing litigation without an upfront payment, while leaving court approval and earlier-entry provisions to resolve.
Victor Sage
Victor Sage
16 Oct 2026
BLS Pharmaceuticals has opened FY27 with record quarterly revenue, positive operating cash flow and reaffirmed full-year guidance. The report contains conflicting Q1 revenue figures of $26.7 million and $27.5 million, while its Scotland expansion remains subject to regulatory approval.
Victor Sage
Victor Sage
15 Oct 2026
Firebrick Pharma has raised approximately $732,000 from strategic investors, with its Philippines licensing partner investing $631,750 to lift its holding above 10%. The funding will support US retail production, a Singapore product launch and working capital.
Ada Torres
Ada Torres
12 Oct 2026
LTR Pharma has completed the final Phase II pharmacokinetic report for SPONTAN, confirming a median 10-minute time to peak concentration against 60 minutes for an oral vardenafil tablet. The result completes the FDA-aligned dataset ahead of planned US submission work, although efficacy in erectile dysfunction patients remains to be tested.
Victor Sage
Victor Sage
1 Oct 2026
Mayne Pharma has settled patent litigation with Sun Pharma over IMVEXXY, establishing 21 October 2032 as the agreed potential generic entry date, subject to court approval. The settlement involves no upfront payment, while one further Paragraph IV dispute remains unresolved.
Victor Sage
Victor Sage
30 Sept 2026
Paradigm Biopharmaceuticals has entered voluntary administration after its pivotal Phase 3 trial produced an interim efficacy result below the threshold required for continuation. The company’s securities will remain suspended while administrators assess its viability, liabilities and possible restructuring options.
Ada Torres
Ada Torres
30 Sept 2026
Firebrick Pharma has received a $293,000 R&D Tax Incentive payment linked to $673,000 of eligible development spending on new Nasodine products. The non-dilutive cash arrives as the company broadens its product range and pursues approvals in additional markets.
Ada Torres
Ada Torres
23 Sept 2026
Avenira Limited (ASX: AEV) has pushed back the closing date of its $48.87 million renounceable rights issue by a week, responding to shareholder demand and expanding eligibility to overseas investors.
Ada Torres
Ada Torres
4 Sept 2026
BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.
Victor Sage
Victor Sage
31 Aug 2026
Island Pharmaceuticals has obtained regulatory rights to reference critical Marburg-Angola virus natural history data, clearing a significant FDA hurdle for its antiviral Galidesivir. This milestone accelerates the path toward pivotal animal studies and potential FDA approval under the Animal Rule.
Victor Sage
Victor Sage
31 Aug 2026

Browse the archive

Full archive